Carcinoma Prostate Clinical Trial
Official title:
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study
Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study
This is a monocentric, single arm, prospective clinical trial designed to obtain explorative information about the effect of Cabozantinib on bone in prostate cancer patients with bone metastatic castration resistant disease, previously treated with two taxanes and at least one next generation hormonal agent. Activity of bone metastatic disease will be assessed by WB-DW-MRI, while changes in bone metabolism will be studied through DXA scan and soluble biomarkers ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03323879 -
Combined LDR Boost and HDR Whole Gland
|
Phase 1/Phase 2 | |
| Completed |
NCT01939743 -
Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate
|
Phase 2 | |
| Completed |
NCT03103724 -
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|